Outcomes
toxicities, DLTs
ADVERSE EVENTS, DISEASE
Dose-limiting toxicities (DLTs) were defined as any treatment-emergent adverse events of grade ≥3 occurring during cycle 1 of the treatment phase that could not be attributed to any cause other than treatment with avapritinib.Clinical benefit rate was defined as the proportion of patients achieving complete response, partial response, or stable disease, each maintained for at least 4 periods after beginning treatment.